Article first published online: 12 JUN 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 57, Issue 6, pages 2143–2154, June 2013
How to Cite
Sulkowski, M. S., Asselah, T., Lalezari, J., Ferenci, P., Fainboim, H., Leggett, B., Bessone, F., Mauss, S., Heo, J., Datsenko, Y., Stern, J. O., Kukolj, G., Scherer, J., Nehmiz, G., Steinmann, G. G. and Böcher, W. O. (2013), Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology, 57: 2143–2154. doi: 10.1002/hep.26276
Potential conflict of interest: Dr. Asselah was on the speakers' bureau of, and received grants from Boehringer-Ingelheim. Dr. Ferenci advises, is on the speakers'™ bureau of, and received grants from Roche and Boehringer-Ingelheim. Dr. Mauss advises and is on the speakers'™ bureau of Boehringer-Ingelheim and Roche. Dr. Sulkowski advises and recieved grants from Abbott, Boehringer-Ingerlheim, Bristol-Myers Squibb, Janssen, Merck, Roche, and Vertex. He advises Gilead, Novartis, and Pfizer.
This work was supported by Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany). Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Clair Thomas, of StemScientific, during the preparation of this manuscript.
- Issue published online: 12 JUN 2013
- Article first published online: 12 JUN 2013
- Accepted manuscript online: 28 JAN 2013 12:55PM EST
- Manuscript Accepted: 23 DEC 2012
- Manuscript Revised: 18 DEC 2012
- Manuscript Received: 17 SEP 2012
- Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany)
- Boehringer Ingelheim, was provided by Clair Thomas, of StemScientific, during
Additional Supporting Information may be found in the online version of this article.
|HEP_26276_sm_SuppTab1.doc||74K||Supporting Information Table|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.